公开(公告)号：US20240376128A1

公开(公告)日：2024-11-14

申请号：US18684203

申请日：2022-08-17

Applicant: Jacobio Pharmaceuticals Co., Ltd.

Inventor： Hongwei YANG ,  Cunbo MA ,  Panliang GAO ,  Huifeng HAN ,  Peng WANG ,  Runze LI ,  Xiaoyu LIU ,  Yanping WANG ,  Wei LONG ,  Wei ZHANG

IPC: C07D519/00 ,  A61K31/519 ,  A61K31/675 ,  C07F9/6561

Abstract: Provided herein is a compound of Formula (IB), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof or a conjugated form thereof; composition containing the same and the use thereof.

公开(公告)号：US20240059710A1

公开(公告)日：2024-02-22

申请号：US18037801

申请日：2021-11-19

Applicant: Jacobio Pharmaceuticals Co., Ltd.

Inventor： Huifeng HAN ,  Panliang GAO ,  Wenlong ZHANG ,  Cunbo MA ,  Peng WANG ,  Dan LIU ,  Hao ZHANG ,  Wei LONG

IPC: C07D519/00 ,  C07D487/08 ,  A61P35/00

CPC classification number: C07D519/00 ,  C07D487/08 ,  A61P35/00

Abstract: KRAS G12D inhibitors of Formula (I), a composition containing the inhibitor and the use thereof.

公开(公告)号：US20240025918A1

公开(公告)日：2024-01-25

申请号：US18037809

申请日：2021-11-19

Applicant: Jacobio Pharmaceuticals Co., Ltd

Inventor： Huifeng HAN ,  Panliang GAO ,  Wenlong ZHANG ,  Cunbo MA ,  Peng WANG ,  Dan LIU ,  Hao ZHANG ,  Wei LONG

IPC: C07D519/00 ,  C07D487/08

CPC classification number: C07D519/00 ,  C07D487/08

Abstract: Provided are KRAS G12D inhibitors of formula (I), a composition containing the inhibitors, a prodrug thereof, a PROTAC compound thereof and the use thereof.

公开(公告)号：US20240199644A1

公开(公告)日：2024-06-20

申请号：US18280487

申请日：2022-03-07

Applicant: JACOBIO PHARMACEUTICALS CO., LTD.

Inventor： Huifeng HAN ,  Panliang GAO ,  Cunbo MA ,  Peng WANG ,  Wei LONG ,  Hao ZHANG ,  Lei ZHANG ,  Dan LIU

IPC: C07D498/16 ,  A61K31/553 ,  C07D498/22 ,  C07D519/00

CPC classification number: C07D498/16 ,  A61K31/553 ,  C07D498/22 ,  C07D519/00

Abstract: The invention relates to a KRAS G12D inhibitors of formula (I) or formula (IV), a composition containing the inhibitor and the use thereof

公开(公告)号：US20210040089A1

公开(公告)日：2021-02-11

申请号：US16986336

申请日：2020-08-06

Applicant: Jacobio Pharmaceuticals Co., Ltd.

Inventor： Panliang GAO ,  Cunbo MA ,  Peng WANG ,  Dan LIU

IPC: C07D471/04 ,  C07D519/00

Abstract: The invention relates to a KRAS mutant protein inhibitor, as shown by formula (I), a composition containing the inhibitor and the use thereof.

公开(公告)号：US20250034166A1

公开(公告)日：2025-01-30

申请号：US18695384

申请日：2022-09-26

Applicant: Jacobio Pharmaceuticals Co., Ltd.

Inventor： Hongwei YANG ,  Cunbo MA ,  Panliang GAO ,  Huifeng HAN ,  Peng WANG ,  Runze LI ,  Wei ZHANG ,  Xiaoyu LIU ,  Yanping WANG ,  Wei LONG

IPC: C07D519/00

Abstract: Provided are K-Ras mutant protein inhibitors of formula (I), a composition containing the same and the use thereof.

公开(公告)号：US20250019377A1

公开(公告)日：2025-01-16

申请号：US18684205

申请日：2022-08-17

Applicant: JACOBIO PHARMACEUTICALS CO., LTD

Inventor： Hongwei YANG ,  Cunbo MA ,  Panliang GAO ,  Huifeng HAN ,  Peng WANG ,  Runze LI ,  Xiaoyu LIU ,  Yanping WANG ,  Wei LONG ,  Wei ZHANG

IPC: C07D471/04 ,  A61K31/553 ,  A61P35/00 ,  C07D413/14 ,  C07D487/04 ,  C07D519/00

Abstract: A Compound of formula (I) or (II), a stereoisomer thereof, an atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer, a pharmaceutically acceptable salt of the atropisomer, a prodrug thereof, a deuterated molecule thereof or a conjugated form thereof is disclosed:

公开(公告)号：US20190127378A1

公开(公告)日：2019-05-02

申请号：US16307827

申请日：2017-06-07

Applicant: JACOBIO PHARMACEUTICALS CO., LTD.

Inventor： Cunbo MA ,  Panliang GAO ,  Jie CHU ,  Xinping WU ,  Chunwei WEN ,  Di KANG ,  Jinlong BAI ,  Xiaoyan PEI

IPC: C07D471/14 ,  C07D491/107 ,  C07D471/20 ,  C07D413/14 ,  C07D401/04 ,  C07D401/14 ,  A61P35/00

Abstract: Provided are certain novel pyrazine derivatives (I) as SHP2 inhibitors which is shown as formula (I), their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided are fused heterocyclic derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.